Beacon Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 0/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Mohammad Karim

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	25.2%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

CEO

Mohammad Karim (68 yo)

no data

Görev süresi

৳780,000

Tazminat

Mr. Mohammad Ebadul Karim serves as Managing Director and Director at Beacon Pharmaceuticals Limited.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mohammad Karim	MD & Director	no data	৳780.00k	25.21% BDT 6.9b
Md. Uddin	CFO & Head of IT	1.4yrs	Veri yok	Veri yok
Ulfat Karim	Chief Operating Officer & Director	1.3yrs	Veri yok	Veri yok
Mohammad Anisur Khan	Executive Vice President of HR & Admin	no data	Veri yok	Veri yok
Mohammad Hanif	Executive Vice President of Marketing	no data	Veri yok	Veri yok
Sujit Kundo	SVP of Project Management	no data	Veri yok	Veri yok
Monjurul Alam	Chief Executive Officer of Global Business Development	no data	Veri yok	Veri yok
Md. Islam	Senior Vice President of MIS & Audit	no data	Veri yok	Veri yok
S. M. Hoque	SVP of Oncology & Biotech	no data	Veri yok	Veri yok
Khalilur Rahman	Company Secretary	no data	Veri yok	Veri yok
Md. Sahabuddin	Company Secretary	less than a year	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: BEACONPHAR's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Beacon Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024

Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company Secretary

Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023

Beacon Pharmaceuticals PLC Announces Appointment of Jalal Uddin as Chief Financial Officer

Beacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as CFO

Less than half of directors are independent

Recent updates

Beacon Pharmaceuticals PLC to Report Q1, 2025 Results on Oct 29, 2024

Upcoming dividend of ৳2.00 per share

Investor sentiment deteriorates as stock falls 16%

Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024

Beacon Pharmaceuticals PLC to Report Fiscal Year 2024 Results on Sep 29, 2024

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings released: ৳0.95 loss per share (vs ৳0.037 loss in 3Q 2023)

Beacon Pharmaceuticals PLC to Report Q3, 2024 Results on May 12, 2024

New minor risk - Share price stability

New major risk - Earnings quality

Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company Secretary

Beacon Pharmaceuticals PLC to Report Q2, 2024 Results on Jan 28, 2024

First quarter 2024 earnings released: EPS: ৳1.60 (vs ৳0.99 in 1Q 2023)

Full year 2023 earnings released: EPS: ৳2.21 (vs ৳4.05 in FY 2022)

New minor risk - Financial data availability

Upcoming dividend of ৳1.60 per share at 0.7% yield

Beacon Pharmaceuticals PLC to Report Q1, 2024 Results on Nov 13, 2023

Beacon Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023

Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023

Beacon Pharmaceuticals PLC to Report Q3, 2023 Results on Oct 22, 2023

Beacon Pharmaceuticals PLC Announces Appointment of Jalal Uddin as Chief Financial Officer

Beacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as CFO

Third quarter 2023 earnings released: ৳0.037 loss per share (vs ৳0.99 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: ৳1.61 (vs ৳1.07 in 2Q 2022)

Less than half of directors are independent

First quarter 2023 earnings released: EPS: ৳0.99 (vs ৳1.52 in 1Q 2022)

Less than half of directors are independent

Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: ৳0.99 (vs ৳2.01 in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of ৳1.50 per share

Third quarter 2020 earnings released: EPS ৳0.25 (vs ৳0.20 in 3Q 2019)

New 90-day high: ৳103

New 90-day high: ৳84.30

New 90-day low: ৳66.50

Third quarter 2020 earnings released: EPS ৳0.25

Beacon Pharmaceuticals Ltd. to Report Q3, 2020 Results on Jun 25, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi